J. Hurley

发表

Cancer pain management among underserved minority outpatients

C. Cleeland, T. Mendoza, V. Valero, 2002, Cancer.

A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.

J. Slingerland, G. Lopes, I. Reis, 2008, Clinical breast cancer.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

L. Koniaris, M. Jordá, J. Slingerland, 2012, Breast Cancer Research and Treatment.

Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation

Jean L Wright, A. Markoe, C. Takita, 2013, Cancer.

Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.

Jean L Wright, C. Takita, K. Saigal, 2013, Clinical breast cancer.

Breast cancer and human immunodeficiency virus: a report of 20 cases.

C. Gomez-Fernandez, I. Reis, J. Hurley, 2001, Clinical breast cancer.

Pain education for underserved minority cancer patients: a randomized controlled trial.

C. Cleeland, T. Mendoza, V. Valero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of Locoregional Outcome in HER2-Overexpressing Breast Cancer Treated With Neoadjuvant Chemotherapy

Jean L Wright, C. Takita, I. Reis, 2015, American journal of clinical oncology.

Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients

J. Schatz, R. Kahn, D. Kwon, 2019, Journal of oncology.

Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients.

M. Pegram, J. Leone, C. Welsh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of tobacco use and HER2 receptor expression in breast cancer in an ethnically diverse inner-city population.

David J Lee, Stacey L. Tannenbaum, T. Koru-Sengul, 2013 .

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

D. Slamon, C. Gomez-Fernandez, M. Pegram, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients

C. Gomez-Fernandez, M. Pegram, I. Reis, 2013, Breast Cancer Research and Treatment.

Breast cancer patients have improved immune and neuroendocrine functions following massage therapy.

T. Field, G. Ironson, M. Diego, 2004, Journal of psychosomatic research.

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.

P. Blondeel, H. Depypere, V. Cocquyt, 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Cyclosporine A, Alpha-Interferon and Interleukin-2 Following Chemotherapy with BCNU, DTIC, Cisplatin, and Tamoxifen: A Phase II Study in Advanced Melanoma

N. Savaraj, L. Feun, F. Moffat, 2005, Cancer investigation.

Impact of Surgery‐Radiation Interval on Locoregional Outcome in Patients Receiving Neo‐adjuvant Therapy and Mastectomy

C. Takita, I. Reis, Wei Zhao, 2013, The breast journal.

Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.

N. Savaraj, L. Feun, F. Moffat, 1995, Melanoma research.

Locoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation

C. Takita, I. Reis, Wei Zhao, 2014, Medicine.

Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2− Breast Cancer

C. Takita, K. Saigal, I. Reis, 2017, American journal of clinical oncology.

Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer.

I. Reis, C. Welsh, J. Hurley, 2005, Clinical breast cancer.

A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma

C. Mies, P. Cassileth, S. Richman, 1998, Cancer.

A comprehensive evaluation of outcomes for inflammatory breast cancer

T. Zimmers, L. Koniaris, M. Byrne, 2009, Breast Cancer Research and Treatment.

African-American and low-socioeconomic status patients have a worse prognosis for invasive ductal and lobular breast carcinoma: do screening criteria need to change?

L. Koniaris, A. Livingstone, Michael C. Cheung, 2009, Journal of the American College of Surgeons.

Recurrent Urothelial Bladder Cancer Among HIV-Infected Patients

Pa-C, P. Ferron, Allan E. Rodriguez, 2009 .

NATURAL KILLER CELLS AND LYMPHOCYTES INCREASE IN WOMEN WITH BREAST CANCER FOLLOWING MASSAGE THERAPY

T. Field, G. Ironson, M. Hernandez-Reif, 2005, The International journal of neuroscience.

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

J. Slingerland, G. Lopes, I. Reis, 2010, Breast Cancer Research and Treatment.

A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma

N. Savaraj, L. Feun, J. Hurley, 2000 .

Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers.

C. Gomez-Fernandez, I. Reis, J. Hurley, 2004, Clinical breast cancer.

Are Many Community Hospitals Undertreating Breast Cancer?: Lessons From 24,834 Patients

L. Koniaris, N. Housri, E. Perez, 2008, Annals of surgery.

Prognostic Factors for Locoregional Recurrence in HER-2 Overexpressing Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

C. Takita, I. Reis, J. Villasboas, 2011 .

Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation

L. Koniaris, C. Takita, M. Jordá, 2011, Breast Cancer Research and Treatment.

Higher chest wall dose results in improved locoregional outcome in patients receiving postmastectomy radiation.

C. Takita, I. Reis, Wei Zhao, 2010, International journal of radiation oncology, biology, physics.

Phase II Trial of Paclitaxel and Dacarbazine with Filgrastim Administration in Advanced Malignant Melanoma

N. Savaraj, L. Feun, J. Hurley, 2002, Cancer investigation.

Predictors of Locoregional Outcome in HER2-Overexpressing Breast Cancer Treated With Neoadjuvant Chemotherapy

C. Takita, I. Reis, Wei Zhao, 2015, American journal of clinical oncology.

Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.

C. Takita, M. Jordá, I. Reis, 2012, Breast.

High rate of axillary node clearence with neoadjuvant Herceptin, Taxotere, and Cisplatin in locally advanced advanced and inflammatory breast cancer

C. Gomez-Fernandez, I. Reis, J. Hurley, 2001 .